Posts

Posted on

Whitestone REIT Commences Transformation of Merchandising Mix at Davenport Village in Austin, Texas

Positioning asset to become an 18-hour activity hub that better serves the lifestyle needs of the surrounding community

Meets neighborhood demand for an upscale coffeehouse, premium fitness concepts and executive suites by bringing in Starbucks Reserve, Pvolve, RVE Fitness and CUBExec

HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE: WSR), a neighborhood-focused owner and operator of open-air shopping centers in Texas and Arizona, today announced that it has commenced a strategic transformation of the merchandising mix at Davenport Village (“Davenport”) in Austin, Texas that is expected to re-energize the center and strengthen its competitive position within the upscale neighborhoods it serves: Davenport Ranch, Westlake, Rob Roy and Barton Creek. Whitestone is creating a vibrant, 18-hour activity hub that more appropriately serves the lifestyle needs of the area and offers greater optionality for West Austin’s large number of seasoned entrepreneurs and business professionals. To support its vision for Davenport, Whitestone has signed agreements with several exciting and esteemed brands that are expected to drive engagement and traffic at the center throughout the day, including Starbucks Reserve, Pvolve, RVE Fitness and CUBExec.

“Davenport is one of the best located retail properties in the country given the large tech workforce surrounding it, and we believe that by strategically transforming the merchandising mix, we will drive greater activity at the center, better serve the surrounding community and increase the value of the property benefiting our shareholders, tenants and community neighbors. Now is the appropriate time to undertake this effort, as the area has lacked a grouping of businesses that provide comprehensive solutions to the area’s lifestyle needs, and we are excited to deliver a much needed solution. Coffee and fitness are proven traffic drivers with natural synergies that support the rest of Davenport’s merchandising mix, and the executive suites will only strengthen the number of people who frequent the center each day.” 

– Dave Holeman, CEO of Whitestone REIT

RESERVE

®

AND RELAX


Starbucks Reserve



®


: Starbucks, the world’s largest coffeehouse chain, will be opening a 3,274-square-foot Reserve® location this summer. Unlike traditional Starbucks cafes, Reserve® locations offer educational aspects of coffee roasting and feature coffee bars that serve Starbucks’ premium, high-end Reserve® line of coffee and display hand-painted murals created by local artists.

The Reserve® at Davenport will be designed to spotlight Starbucks’ exquisite Reserve® coffee and showcase its heritage, expertise and dedication to coffee craft through interactive coffee experiences where barista craft is the cornerstone. Moreover, custom artwork developed by Austin-based artists will be featured throughout the space, adding to the ambiance and helping to deepen the connection Austinites have with their beloved city.

THE SOLUTION TO THE PVOLVE-UTION


Pvolve

: Actress Jennifer Aniston’s favorite low-impact fitness method will open a 3,126-square-foot studio by the spring. Pvolve is a workout method that pairs functional movement with resistance equipment to build strong, mobile bodies, so members can live younger, longer.

The Pvolve Method is supported by a Clinical Advisory Board of doctors, as well as highly credentialed trainers, to offer effective workouts that help you break a sweat, not your body.

RaVE’n ABOUT IT


RVE Fitness

: The luxury fitness brand specializes in offering its members an unparalleled fitness and wellness experience. The 7,815-sqaure-foot-space will feature a wellness center and gym, with a variety of classes and services available to enhance overall well-being. From cardio and strength training equipment, to group fitness classes, to yoga and Pilates, to massage therapy, to sauna and steam rooms, to nutrition counseling, they have something for everyone.

RVE Fitness will be operated by Esteban Sandoval and Adam Mata, two Austin-based attorneys who are fiercely committed to health and wellness. The duo decided to open the franchise at Davenport because they were members at the center’s previous gym and enjoyed the ability to work out in their own neighborhood but craved a facility that offered a higher-end experience with top-notch amenities and services.

As such, Sandoval and Mata saw a tremendous opportunity to bring the luxury fitness brand to Davenport and quickly build a large and loyal membership given the center’s strong traffic numbers and strategic location in the heart of tech-rich West Austin. The gym and wellness center will open in the fall and feature private changing rooms and showers.

EXECUTIVE SUITES FOR ENTREPRENEUR MEETS


CUBExec

: In an effort to better connect Austin’s seasoned entrepreneurs and growing business community with one another, Whitestone prioritized adding CUBExec, a brand specializing in offering appealing executive suites and professional conference space.

CUBExec will be connected to RVE Fitness for added convenience and on-demand fitness, and several of its executive suites will be available for rent by the first quarter of 2026. The addition of CUBExec provides the workforce in West Austin with an intriguing and convenient option for networking and privacy without having to commute to downtown, a preference born out of the pandemic.

“The additions of Starbucks Reserve

®

, Pvolve, RVE Fitness and CUBExec are bespoke solutions for this high-end section of West Austin. All of them are very selective in where they open locations, prioritizing growing neighborhoods that are in proximity to a robust and well-educated workforce. What’s unique about Whitestone is our portfolio of holdings is concentrated in markets like this and that is why we can attract upscale brands, which are all about fostering engagement with the neighborhoods they serve and are a strong match with Whitestone’s ethos of creating local connections within our communities.”

– 

Christine Mastandrea, COO of Whitestone REIT

Davenport, located at 3801 North Capital of Texas Highway, is situated amidst the bustling hub of high-tech companies and is just minutes from the Apple and Tesla campuses. The average household income within a three-mile radius of the center surpasses $247,790 while the average home values total more than $1.28 million. Austin Country Club and St. Stephens Episcopal School are both in close proximity to the property and continue to drive traffic and spur development in the area.

About Whitestone REIT

Whitestone REIT (NYSE: WSR) is a community-centered real estate investment trust (REIT) that acquires, owns, operates, and develops open-air, retail centers located in some of the fastest growing markets in the country: Phoenix, Austin, Dallas-Fort Worth, Houston and San Antonio.

Our centers are convenience focused: merchandised with a mix of service-oriented tenants providing food (restaurants and grocers), self-care (health and fitness), services (financial and logistics), education and entertainment to the surrounding communities. The Company believes its strong community connections and deep tenant relationships are key to the success of its current centers and its acquisition strategy. For additional information, please visit the Company’s investor relations website.

Forward-Looking Statements

This Report contains forward-looking statements within the meaning of the federal securities laws, including discussion and analysis of our financial condition, pending acquisitions and the impact of such acquisitions on our financial condition and results of operations, anticipated capital expenditures required to complete projects, amounts of anticipated cash distributions to our shareholders in the future and other matters. These forward-looking statements are not historical facts but are the intent, belief or current expectations of our management based on its knowledge and understanding of our business and industry. Forward-looking statements are typically identified by the use of terms such as “may,” “will,” “should,” “potential,” “predicts,” “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates” or the negative of such terms and variations of these words and similar expressions, although not all forward-looking statements include these words. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.

Factors that could cause actual results to differ materially from any forward-looking statements made in this Report include: the imposition of federal income taxes if we fail to qualify as a real estate investment trust (“REIT”) in any taxable year or forego an opportunity to ensure REIT status; uncertainties related to the national economy, the real estate industry in general and in our specific markets; legislative or regulatory changes, including changes to laws governing REITs; adverse economic or real estate developments or conditions in Texas or Arizona, Houston and Phoenix in particular, including the potential impact of COVID-19 on our tenants’ ability to pay their rent, which could result in bad debt allowances or straight-line rent reserve adjustments; inflation and increases in interest rates, operating costs or general and administrative expenses; availability and terms of capital and financing, both to fund our operations and to refinance our indebtedness as it matures; decreases in rental rates or increases in vacancy rates; litigation risks; lease-up risks, including leasing risks arising from exclusivity and consent provisions in leases with significant tenants; our inability to renew tenant leases or obtain new tenant leases upon the expiration of existing leases; our inability to generate sufficient cash flows due to market conditions, competition, uninsured losses, changes in tax or other applicable laws; geopolitical conflicts, such as the ongoing conflict between Russia and Ukraine; the need to fund tenant improvements or other capital expenditures out of operating cash flow; and the risk that we are unable to raise capital for working capital, acquisitions or other uses on attractive terms or at all and other factors detailed in the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other documents the Company files with the Securities and Exchange Commission from time to time.

Contacts:

For Whitestone REIT – Investors
David Mordy
(713) 435-2219
[email protected]

For Whitestone REIT – Media:
Matthew Chudoba
[email protected]



Posted on

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

Webcast scheduled for Tuesday, March 25 at 8:00 am ET

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it will host a virtual event to provide an overview of the commercialization strategy, plans and progress for sebetralstat, the Company’s investigational treatment for hereditary angioedema (HAE). The event will take place on Tuesday, March 25, 2025, from 8:00 a.m. to 10:00 a.m. ET. To register, please click here.

In addition to presentations by KalVista’s management team, leading external experts in HAE will discuss the current treatment guidelines and unmet needs for people living with HAE, and how sebetralstat could provide a new treatment option. A live question-and-answer session will follow the formal presentations.

The live webcast and accompanying slides will be accessible through the Investors section of the Company’s website at ir.kalvista.com. A replay of the webcast will be available following the event.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the U.S. FDA, with a PDUFA goal date of June 17, 2025. In addition, we have completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other global regulatory authorities.

For more information about KalVista, please visit www.kalvista.com or follow us on social media at @KalVista and LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Ryan Baker

Head, Investor Relations

(617) 771-5001

[email protected]

Molly Cameron

Director, Corporate Communications

(857) 356-0164

[email protected]

KEYWORDS: Europe United States United Kingdom North America Massachusetts

INDUSTRY KEYWORDS: Health Clinical Trials Research Pharmaceutical Science Biotechnology

MEDIA:

Logo
Logo
Posted on

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

– Second major approval for WAINZUA, which is marketed in the U.S. as WAINUA™ –

– EU approval based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo –

CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis and AstraZeneca’s WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, commonly referred to as hATTR-PN or ATTRv-PN. WAINZUA is the only approved medicine in the EU for the treatment of ATTRv-PN that can be self-administered monthly via an auto-injector.

The approval by the European Commission (EC) follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP). The approval is based on the positive NEURO-TTRansform Phase 3 trial which showed that through 66 weeks, patients treated with WAINZUA demonstrated consistent and sustained benefit on the co-primary endpoints of serum transthyretin (TTR) concentration and neuropathy impairment measured by modified Neuropathy Impairment Score +7 (mNIS+7), and key secondary endpoint of quality of life (QoL) on the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) versus external placebo. WAINZUA continued to demonstrate a favorable safety and tolerability profile throughout the NEURO-TTRansform trial.

ATTRv-PN is a debilitating disease that leads to peripheral nerve damage with motor disability within five years of diagnosis and, without treatment, is generally fatal within a decade. WAINZUA is a once-monthly RNA-targeted medicine designed to reduce the production of TTR protein at its source.

“Today’s approval of WAINZUA in Europe offers adults with hereditary transthyretin-mediated amyloidosis with polyneuropathy a new, self-administered treatment option that provides consistent suppression of transthyretin production and improves neuropathy impairment and quality of life,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “With approvals in North America, UK and now across the EU, we are proud of the continued progress as we and our partner, AstraZeneca, rapidly and effectively deliver WAINZUA to people around the world.”

WAINZUA was approved under the brand name WAINUA for the treatment of ATTRv-PN in the U.S. in December 2023 and has gained approvals in additional countries worldwide, including Canada and the United Kingdom. As part of a global development and commercialization agreement, AstraZeneca and Ionis are jointly developing and commercializing WAINUA in the U.S. The companies are seeking regulatory approval in other parts of the world where AstraZeneca has exclusive rest of world commercialization and development rights.

About TTR Amyloidosis

ATTR is caused by the accumulation of liver-derived misfolded TTR protein in tissues, such as the heart and the peripheral nerves, causing organ damage and failure. ATTR then causes complications, leading to cardiovascular, neurological and renal diseases such as heart failure and chronic kidney disease. There are both hereditary (ATTRv) and non-hereditary (wild-type) forms of ATTR. ATTR is a rapidly progressive and fatal disease that requires timely recognition of symptoms. ATTR has several phenotypes including ATTR-cardiomyopathy (CM), which predominantly impacts the heart, potentially leading to heart failure, ATTR-polyneuropathy (PN), which predominantly affects the peripheral nervous system and mixed phenotype, where patients experience symptoms of both. Worldwide, there are an estimated 300,000 – 500,000 patients with ATTR-CM and about 10,000 – 40,000 patients with ATTRv-PN.

About NEURO-TTRansform

NEURO-TTRansform is a global, open-label, randomized trial evaluating the efficacy and safety of eplontersen in patients with ATTRv-PN at week 35, week 66 and week 85. The final analysis comparing eplontersen to an external placebo group was completed at week 66. All patients were then followed on treatment until week 85 and evaluated four weeks after the last dose in an end-of-trial assessment. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving eplontersen once every four weeks or enter a 20-week post-treatment evaluation period, which is still ongoing. Full results from the NEURO-TTRansform trial were published in The Journal of the American Medical Association (JAMA) demonstrating the benefit of eplontersen across the spectrum of ATTRv-PN at 35, 66 and 85 weeks of treatment.

About WAINZUA / WAINUA™ (eplontersen)

Eplontersen is a once-monthly RNA-targeted medicine that provides upstream suppression of transthyretin (TTR) production and is designed to precisely target and reduce the production of TTR protein at its source in the liver.

WAINZUA has been approved in the U.S. and Canada under the brand name WAINUA™ (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN. Please see link for full U.S. Prescribing Information.

Eplontersen is also currently being evaluated in the global CARDIO-TTRansform Phase 3 study for the treatment of adults with ATTR-CM. The trial is fully enrolled with more than 1,400 patients – making it the largest, most comprehensive study to date in this patient population. More information on the CARDIO-TTRansform study (NCT04136171) is available at www.clinicaltrials.gov.

U.S. INDICATION for WAINUA™ (eplontersen)

WAINUA injection for subcutaneous use 45 mg is indicated for treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

IMPORTANT SAFETY INFORMATION for WAINUA™ (eplontersen)

WARNINGS AND PRECAUTIONS

Reduced Serum Vitamin A Levels and Recommended Supplementation WAINUA leads to a decrease in serum vitamin A levels. Supplement with recommended daily allowance of vitamin A. Refer patient to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur.

ADVERSE REACTIONS

Most common adverse reactions (≥9% in WAINUA-treated patients) were vitamin A decreased (15%) and vomiting (9%).

Please see link to U.S. Full Prescribing Information for WAINUA.

About Ionis Pharmaceuticals, Inc.

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

Ionis Forward-looking Statements

This press release includes forward-looking statements regarding Ionis’ business and the therapeutic and commercial potential of our commercial medicines, eplontersen, additional medicines in development and technologies. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions, or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis’ programs are described in additional detail in Ionis’ annual report on Form 10-K for the year ended Dec. 31, 2024, and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com.

Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc. WAINUA™ is a trademark of AstraZeneca plc.

Ionis Investor Contact:

D. Wade Walke, Ph.D.

[email protected] 760-603-2331

Ionis Media Contact:

Hayley Soffer

[email protected] 760-603-4679

KEYWORDS: Europe United States North America California

INDUSTRY KEYWORDS: Health Infectious Diseases Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.–(BUSINESS WIRE)–
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 113,200 shares of the company’s common stock to nine new employees (the “New-Hire Inducement Grants”) on March 3, 2025.

The New-Hire Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on March 3, 2025. The New-Hire Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to each employee’s continued employment with Viridian through the applicable vesting dates.

Viridian also announced that the company’s Board of Directors approved the grant of non-qualified stock options to Radhika Tripuraneni, who was recently appointed to the role of Chief Medical Officer (“CMO”), to purchase 310,700 shares of the company’s common stock (the “CMO Inducement Grant”) effective as of March 10, 2025 (the “CMO Grant Date”).

The CMO Inducement Grant has an exercise price per share that is equal to the closing price of Viridian’s common stock on the CMO Grant Date. The CMO Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the CMO Grant Date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to Dr. Tripuraneni’s continued employment with Viridian through the applicable vesting dates.

The New-Hire Inducement Grants and the CMO Inducement Grant have been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan. The New-Hire Inducement Grants and the CMO Inducement Grant were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).

About Viridian Therapeutics

Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Both THRIVE and THRIVE-2 reported positive topline data, meeting all the primary and secondary endpoints of each study. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED.

In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn and X.

Anabel Chan, 617-458-8725

Vice President, Investor Relations & Communications

[email protected]

Louisa Stone, 617-272-4604

Senior Manager, Investor Relations & Communications

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Optical Clinical Trials

MEDIA:

Logo
Logo
Posted on

Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference

Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference

LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference in Miami, Florida.

Dr. Brady’s conversation with Marc Goodman, Senior Managing Director, Neuroscience, is scheduled to begin at 9:20 a.m. ET Monday, March 10, 2025. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following the fireside chat, the webcast will be archived for 90 days.

About Aldeyra

Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.

Investor & Media Contact:

Laura Nichols

Tel: (781) 257-3060

[email protected]

KEYWORDS: United States North America Florida Massachusetts

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Optical Health

MEDIA:

Posted on

Celsius Holdings to Participate in Upcoming Investor Conferences

Celsius Holdings to Participate in Upcoming Investor Conferences

BOCA RATON, Fla.–(BUSINESS WIRE)–Celsius Holdings, Inc. (Nasdaq: CELH) today announced that the company will participate in the following investor conferences:

UBS Global Consumer and Retail Conference

Date: March 12, 2025

Fireside chat: March 12, approximately 9:00 a.m. ET

37th Annual Roth Conference

Dates: March 17-18, 2025

Fireside chat: March 18, approximately 3:30 p.m. ET

All investors are invited to join live webcasts of the fireside chat events at https://ir.celsiusholdingsinc.com/events-and-presentations/. As disclosed in our Annual Report on Form 10-K filed with the Securities & Exchange Commission (the “SEC”) on March 3, 2025, we use our website and webcasts as means of disclosing material information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Attendees are reminded to join the webcast before the planned start time to ensure a good connection and to allow for time to complete the free registration. We intend to make replays of the webcast noted above available on our website for at least 90 days after the original conference date.

About Celsius Holdings, Inc.

Celsius Holdings, Inc. (Nasdaq: CELH) is a leading better-for-you, functional lifestyle platform and the owner of energy drink brand CELSIUS® and hydration brand CELSIUS HYDRATIONTM. Born in fitness and pioneering the rapidly growing, better-for-you functional beverage category, the company creates and markets leading functional beverage products. For more information, please visit www.celsiusholdingsinc.com.

Investor Relations Contact:

Paul Wiseman

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Retail Health Convenience Store Other Retail Supermarket Fitness & Nutrition Food/Beverage

MEDIA:

Logo
Logo
Posted on

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

FT. MYERS, Fla.–(BUSINESS WIRE)–NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology testing services, today announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. The acquisition strengthens NeoGenomics’ commercial presence in the Northeast U.S., expanding its service capabilities and accelerating growth in molecular and hematology-oncology testing by establishing a local presence for the company in a historically under penetrated but rapidly growing geographical region of the country.

Founded in 2009, Pathline serves a long-standing client base of hospitals, cancer centers, and physician practices, with approximately 98% of its revenue coming from customers in the Northeast. It offers a comprehensive suite of subspecialty pathology services, including histopathology, immunohistochemistry, cytology, cytogenetics, flow cytometry, fluorescence in situ hybridization (FISH), and molecular pathology.

“The acquisition of Pathline presents a strategic opportunity because it brings New York State (NYS) approvals and when combined with our rapid turnaround times and leading customer experience will enable us to accelerate growth to what has historically been an underpenetrated region,” said Warren Stone, Chief Commercial Officer at NeoGenomics. “We have deeper penetration rates in areas where we have close proximity to a lab like California, Florida and Texas. Integrating Pathline’s operations into NeoGenomics’ national network will further enhance our ability to support oncologists, healthcare institutions and patients in the Northeast region.”

“As part of NeoGenomics, we are excited to leverage our expertise and strong oncology testing capabilities to reach more patients and healthcare providers,” said Dr. Zach Liu, Chief Medical Officer and Laboratory Director at Pathline. “Our team has built a trusted laboratory serving hospitals and oncology practices across the Northeast, and we look forward to continuing to improve cancer care by expanding access to advanced molecular testing for the patients that we serve under the NeoGenomics banner moving forward.”

Leveraging its differentiated commercial infrastructure, NeoGenomics expects to grow incremental topline revenue with contributions from the acquired business while operational consolidation efforts and synergies are expected to yield substantial annual cost reductions, which will be accretive to AEBITDA starting in 2026.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company’s ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company’s other filings with the Securities and Exchange Commission.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Investor Contact

Kendra Sweeney

[email protected]

Media Contact

Andrea Sampson

[email protected]

KEYWORDS: United States North America Florida New Jersey

INDUSTRY KEYWORDS: Oncology Health Hospitals Genetics Managed Care Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum

Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in a fireside chat at the KeyBanc Capital Markets Virtual Healthcare Investor Forum on Tuesday, March 18, 2025, at 2:15 p.m. Eastern Time. In addition, Mr. O’Connor will host one-on-one meetings with institutional investors throughout the day.

A live webcast of the fireside chat can be accessed via this link and also on the Investors page of the Simulations Plus website where it will be available for replay for approximately 90 days following the event.

About Simulations Plus, Inc.

With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | X | YouTube.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update.

Financial Profiles

Lisa Fortuna

310-622-8251

[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Research Technology Consulting Clinical Trials Professional Services Software Biotechnology Pharmaceutical Health Science

MEDIA:

Logo
Logo
Posted on

Voyager and Palantir Developing AI-Powered Solution for Space Domain Awareness Applications

PR Newswire

System to perform space-based object detection, identification, classification and
tracking


DENVER
, March 10, 2025 /PRNewswire/ — Voyager Technologies (Voyager), a global leader in defense technology and space solutions, is expanding its partnership with Palantir Technologies (NASDAQ: PLTR) to develop AI-powered solutions for enhanced Space Domain Awareness, enabling the proactive mitigation of potential collisions and threats.

“Our partnership is driving resilience into national security space by providing decision-makers with critical information on operationally relevant timescales,” said Matt Magaña, President of Defense and National Security at Voyager. “We’re developing an integrated solution, harnessing the power of AI with Palantir’s software stack and taking advantage of real-time radio frequency streams and imagery to perform space-based object detection, identification, classification and tracking.”

The open-architecture SDA system pulls data from existing on-orbit assets using Voyager’s VPX signal processing electronics and chassis, signals intelligence software and mission services capabilities and Palantir’s AI/Machine-Learning engines. The team aims to rapidly transition the SDA system from TRL4 to TRL8 as a hosted payload in 2026.

“We are deepening our partnership with Voyager to deliver the transformative capabilities required to maintain our national security,” said Robert Imig, Head of USG Research and Development at Palantir. “We are further extending the reach of our AI solutions from ground to space, a critical frontier where demands are intensifying as the environment grows increasingly contested.”

Palantir’s AI capabilities will enhance Voyager’s defense and national security solutions, enabling in situ signals processing for optical communication systems and more.

To learn more about Voyager’s next-generation defense technologies please visit: https://voyagertechnologies.com/defense-natsec/

About Voyager Technologies:

Voyager Technologies (Voyager) is a defense and space technology company committed to advancing and delivering transformative, mission-critical solutions. By tackling the most complex challenges, Voyager aims to unlock new frontiers for human progress, fortify national security, and protect critical assets from ground to space. For more information visit: voyagertechnologies.com

Cautionary Statement Concerning Forward-Looking Statements

This press release contains “forward-looking statements.” All statements, other than statements of historical fact, including those with respect to Voyager Technologies Inc.’s (the “Company’s”) mission statement and growth strategy, are “forward-looking statements.” Although the Company’s management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve many risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated. Potential risks and uncertainties include, among others, general economic conditions and conditions affecting the industries in which the Company operates; the uncertainty of regulatory requirements and approvals; and the ability to obtain necessary financing on acceptable terms or at all. Readers should not place any undue reliance on forward-looking statements since they involve these known and unknown uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons that actual results could differ materially from those.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/voyager-and-palantir-developing-ai-powered-solution-for-space-domain-awareness-applications-302396249.html

SOURCE Voyager Technologies

Posted on

Priceline’s Getting Travelers off the Sidelines and to their Dream Destinations with Newest Campaign

PR Newswire

This March college basketball fans can save as much as 50% off game-day travel with Priceline’s new ‘Buzzer Beater’ deals for the biggest matchups of the season


NORWALK, Conn.
, March 10, 2025 /PRNewswire/ — Priceline’s newest integrated campaign, launching today, is waking travelers from their “dreamscrolling” and showing them that their bucket-list vacations are closer than they think. This campaign is rooted in a powerful realization that Americans are spending hours “dreamscrolling,” the modern habit of endlessly browsing travel content without ever actually booking the trip. Priceline’s new campaign is designed to inspire young travelers to get off their phones and take the real-life trips they are dreaming of.

In a 2024 survey commissioned by Priceline, over half of Millennial and Gen Z consumers said they dream about vacation plans every week, yet barriers like price and complexity hold them back. With Priceline’s millions of deals, travelers can make that dream trip happen – whether it’s catching a buzzer-beater shot live or finally booking that bucket list vacation.

Stop Scrolling and Book It with Priceline: New Ad Campaign Featuring Kaley Cuoco
To help combat the dreamscrolling phenomena, the campaign, starring Kaley Cuoco, is all about waking travelers from their daydreams to show them that their bucket-list trips are within reach. Each ad features a person who is lost in a pink-cloud world fantasizing about their perfect getaway. Suddenly, a whimsical travel guru, played by Cuoco, disrupts their dream and encourages them to stop dreaming about a trip and start booking with Priceline.

“I love being part of Priceline’s mission to help turn their dream trips into a reality,” said Kaley Cuoco. “This campaign is all about reminding travelers that their ‘happy place’ is closer than they think — it’s just a flight, a hotel, a deal away. I hope it inspires everyone to finally take the trip they’ve always wanted.”

The campaign tips off with a basketball-themed spot premiering this week. In the ad, a passionate fan dreams of himself in a stadium watching his favorite team compete to win it all, only to be jolted awake when Cuoco – floating inside a spinning basketball – reminds him that with Priceline’s unbeatable deals, he can finally experience the excitement in real life.

“Travel has the power to turn dreams into reality, and with Priceline, that reality is more accessible than ever,” said Lesley Klein, SVP, Strategy and Brand Marketing at Priceline. “This campaign is all about breaking down the barriers that keep people on the sidelines – whether that’s cost, hesitation, or just the feeling that travel is out of reach. By delivering unbeatable deals and exciting partnerships, we’re making it easier than ever for travelers to stop dreaming and start going.”

‘Buzzer Beater’ Deals: Limited-Time Offers for Basketball Fans

1

Just in time for the height of the college basketball season, the integrated campaign continues with ‘Buzzer Beater’ deals, offering big savings for the biggest tournament of the season. These first-of-their-kind offers provide ‘buzzer-beater’ discounts for fans looking to catch the action live as their favorite teams advance to the final brackets. Fans can score deals on hotels in the Men’s and Women’s tournament host cities for a limited time before each round, from March 25 to April 6, including:

  • Top 16: save 10% on select hotels in:

    • Men’s Tournament: Newark, NJ & San Francisco, CA
    • Women’s Tournament: Birmingham, AL & Spokane, WA
  • Quarter-Finals: save 15% on select hotels in:

    • Men’s Tournament: Atlanta, GA & Indianapolis, IN
    • Women’s Tournament: Birmingham, AL & Spokane, WA
  • Semi-Finals: save $125 on select hotels in:

    • Men’s Tournament: San Antonio, TX
    • Women’s Tournament: Tampa, FL
  • Championships: save $250 on select hotels in:

    • Men’s Tournament: San Antonio, TX
    • Women’s Tournament: Tampa, FL

Unlock Priceline’s ‘Buzzer Beater’ deals here.

To up the ante even more, on March 1st Priceline will upgrade customers with .edu email addresses to VIP Gold status for the remainder of 2025. This upgraded loyalty status will unlock even more exclusive travel discounts so students and educators can hit the road and cheer on their schools this March.

Priceline and DraftKings Team Up for a First-Ever Dynamic Bracket Challenge
The madness continues as Priceline and DraftKings team up to host the “Dream It, Book It Bracket” surrounding the Men’s College Basketball Tournament. The challenge will include one free-to-play bracket with a spin: each match-up will feature a first-of-its-kind dynamic custom rollover showcasing real Priceline hotel deals for each host city. Players will score points based on how many correct winning teams they picked through the tournament for a shot at a $50,000 cash prize (that’s a lot of dream trips!). To create your bracket and play for free, visit the entry page on the DraftKings website or app from March 16 through March 20. Age and eligibility restrictions apply. Void where prohibited. See terms at www.draftkings.com/priceline. 

In addition to the interactive bracket and Buzzer Beater Deals, traveling basketball fans can make the most of their trips to the tournament cities with Priceline’s game-day itineraries. Featured across SB Nation and Thrillist, each itinerary is a curation of unique local recommendations for sports fans wherever the games are happening. These comprehensive city guides will provide everything they need to know to extend their game-day experience into a fan’s dream trip.

A Multi-Faceted Campaign to Inspire your Next Bucket-List Vacation
The first ad can be viewed here, with multiple spots rolling out in the coming months.

The campaign will run across broadcast, digital, and social media with extensive takeovers across Meta, TikTok, YouTube, SB Nation, Direct TV, Peacock and more. Additional launch elements include an influencer campaign, and audio and podcast ads. The integrated campaign will continue to build throughout the year with social content designed to entertain, engage and inspire more travel.

For more information and to book your next vacation, visit Priceline or download the Priceline app.

About Priceline
Priceline, part of Booking Holdings Inc. [NASDAQ: BKNG], has been a leader in online travel for twenty-five years. Priceline’s proprietary deals technology pairs negotiation with innovation to analyze billions of data points to generate deep discounts for customers they can’t find anywhere else. Travelers have access to millions of hotels, flights, alternative accommodations, rental cars, cruises, vacation packages and experiences from trusted brands in over 116 countries around the world, 24/7 customer service and incremental savings when becoming a Priceline VIP. By making affordable travel within reach for all, Priceline helps millions of customers each year be there for the moments that matter to them. Because where your happy place meets your happy price, that place is Priceline.

_______________________________


1
 Priceline and Buzzer Beater Deals are not affiliated with the NCAA

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pricelines-getting-travelers-off-the-sidelines-and-to-their-dream-destinations-with-newest-campaign-302396508.html

SOURCE Priceline